The pharmaceutical community is excited with anticipation surrounding retatrutide, a new dual GIP and GLP-1 target that’s showing significant promise in clinical trials for treating obesity. Unlike some available weight loss solutions, retatrutide appears to deliver a greater substantial decrease in body size and improve metabolic function, parti